What this is
- How it works
- How it works isn't classified yet
- Tested for
- Fibromyalgia (2 trials)
- Main trialPhase 3
- “The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.”In the company’s words, NCT07398417 on ClinicalTrials.gov
Coming up2
- Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- May 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Mar 2028 | Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design | |
| Phase 3Enrolling by invitation | May 2028 | Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026